查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1848727

醫院感染控制市場（按產品類型和應用）—全球預測 2025-2032

Hospital Acquired Infection Control Market by Product Type, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，醫院感染控制市場規模將成長至 612 億美元，複合年成長率為 6.71%。

主要市場統計數據
基準年2024年 363.9億美元
預計2025年 387.9億美元
預測年份：2032年 612億美元
複合年成長率（%） 6.71%

權威概述，為現代感染預防策略建立背景，涵蓋技術、臨床環境和供應鏈彈性

院內感染仍然是對病人安全、臨床結果和醫療機構聲譽的持續威脅。病原體譜的演變、監管審查的加強以及對機構層面復原力的不斷提升的期望，使得感染預防成為臨床和營運策略的核心。本簡介從多方面概述了感染控制技術和臨床應用，為深入分析產品類別、護理環境和地理動態奠定了基礎。

當今產業的特點是技術創新快速發展、跨部門協作和供應鏈審查日益嚴格。空氣淨化技術、抗生素塗層、手部衛生配方、器械滅菌平台、表面消毒劑、紫外線系統和水處理流程等創新技術正在整合到更廣泛的感染預防項目中。同時，醫療保健服務模式正轉向跨設施的護理，例如急診科、綜合醫院病房、加護病房、手術室和門診病人設施，每個設施都有不同的感染控制要求和營運限制。這些相互交織的趨勢要求我們採取整合策略策略，將工程控制、表面和器械消毒以及行為導向的合規計劃相結合。

隨著相關人員尋求降低感染發生率的切實可行的途徑，本導言將幫助讀者了解影響採購、臨床政策和資本規劃的關鍵考量。本導言也確立了後續章節中使用的分析視角——重點關注技術有效性、臨床適用性、監管合規性和供應鏈彈性——以指導基於證據的感染控制解決方案的採用和推廣。

技術創新、臨床工作流程重新設計和監管期望的融合如何重塑整個醫療環境中的感染預防

在技​​術進步、監管趨勢和臨床工作流程轉變的推動下，感染預防領域正在經歷一系列變革時期。空氣管理創新正從單一用途的過濾轉向整合系統，該系統結合了高效能空氣微粒子過濾器 (HEPA)過濾、電離技術和針對性紫外線空氣處理技術，以減少高風險區域的氣溶膠病原體含量。表面和設備消毒方法如今結合了成熟的化學方法，包括醇基和氯基消毒劑、過氧化氫化合物、季銨鹽製劑以及汽化過氧化氫和低溫系統等先進的滅菌方法，以構建互補的多層防禦體系。

從黏性導管到銀基表面等留置設備上的抗菌塗層，以及抗菌管理，正在重新評估，以平衡設備相關感染的減少和抗藥性考慮。手部衛生解決方案已多樣化，包括含酒精的凝膠、泡沫和液體，以及抗菌肥皂和一次性擦拭巾，並提供根據工作流程和合規性量身定做的交付形式。紫外線消毒系統已發展成為固定裝置和攜帶式設備，支援有針對性的設備清潔和快速的房間週轉；水處理解決方案現已整合化學劑量、過濾和紫外線處理，以應對管道相關風險。

加護治療和手術室的診療方案正日益以實證醫學主導，並日益儀器化，而急診和門診設施則需要快速、可擴展且不影響診療效率的干涉措施。這些發展正在重塑採購優先事項、資金配置和臨床實踐指南，並促進臨床團隊、設施管理人員和技術提供者之間建立新的合作關係。

評估 2025 年關稅變化對感染控制設備採購、供應鏈彈性和臨床連續性的下游營運和採購影響

2025年實施的關稅和貿易政策調整，正在對感染預防技術​​供應鏈、籌資策略和資本規劃產生連鎖反應。關稅相關的成本壓力正在影響關鍵投入的採購，例如高效空氣過濾器 (HEPA) 系統的過濾介質、塗層設備中使用的特種聚合物以及紫外線消毒設備的組件，促使採購團隊重新評估其供應商組合，並考慮近岸外包和多元化策略，以保持供應的連續性。

為此，許多醫療保健系統和製造商正在進行全面的供應鏈風險評估，並調整合約條款，以納入緊急條款、替代採購路徑以及檢驗任務物品的策略性庫存緩衝。不斷變化的成本動態也影響了進口成品與國產替代品的相對競爭力，推動了對滅菌設備、消毒配方和耗材的國內生產能力的投資。對經過驗證的滅菌製程和產品性能的監管要求進一步加劇了快速更換供應商的複雜性，促使跨職能團隊在合規需求和成本控制之間取得平衡。

在臨床上，這些交易動態促使企業對整體擁有成本（包括耐用性、維護要求和耗材消耗模式）進行更嚴格的評估，而非僅依賴單價。採購和臨床領導者越來越重視與能夠提供服務、培訓和檢驗的性能數據的供應商建立夥伴關係，以降低營運風險。因此，關稅主導的壓力正在加速企業向更具彈性、更多樣化的供應鏈以及臨床、採購和製造相關人員之間更緊密合作的策略調整。

透過細分洞察，為採購和部署策略提供資訊，將特定的感染控制產品類別與不同的臨床環境和操作限制聯繫起來

要深入了解需求促進因素，需要按產品類型和臨床應用進行細分，因為這些維度的交集決定了臨床效用、採購優先順序和採用路徑。按產品分類，空氣淨化技術包括基於 HEPA 過濾器的系統、電離平台和紫外線增強空氣清淨器，每種技術都提供與減輕空氣傳播病原體相關的獨特性能特徵。抗菌塗層，無論是黏合到導管表面或銀基塗層，都旨在降低與器械相關的感染風險，但必須評估其與器械材料的兼容性和抗菌管理問題。手部衛生解決方案包括以凝膠、泡沫或液體形式提供的酒精類消毒劑、抗菌肥皂和一次性濕紙巾，其選擇受工作流程、皮膚耐受性和依從性指標的影響。器械滅菌選項包括蒸氣、環氧乙烷、輻射、低溫和汽化過氧化氫系統，需要在週期時間、材料相容性和吞吐量之間進行權衡。表面消毒劑包括醇基、氯基、過氧化物基和季銨鹽基，每種消毒劑都適用於特定的表面類型和接觸時間要求。紫外線消毒解決方案有固定式和攜帶式形式，每種形式都支援不同的操作模式。同時，水處理策略結合了化學投加、過濾和紫外線處理，以解決管道相關的感染媒介。

此外，水處理策略透過結合化學劑量和紫外線處理來解決與管道相關的感染媒介。急診需要能夠在成人和兒科護理區域提供強大病原體控制的同時保持快速患者流量的解決方案。內科、整形外科和外科病房需要可擴展的干涉措施，並與常規內科和護理工作流程相結合。加護病房護病房涵蓋成人、新生兒和小兒科專科，由於病患的脆弱性和侵入性器械的普遍性，需要最高水準的器械和環境控制。手術室需要協調一致的術中、術前和術後方法，優先考慮無菌和輪轉效率。門診設施，例如門診手術中心和診所，需要感染預防技術​​，以平衡成本效益和法規遵循並提高患者吞吐量。透過選擇針對每個醫療環境細微差別的產品，醫療機構可以實現既能反映臨床需求又能反映營運現實的性能。

影響全球主要醫療保健市場技術選擇、監管協調和支援模式的區域動態和採用模式

區域動態塑造感染預防解決方案的法規環境、技術採用曲線和供應鏈路徑。在美洲，法律規範和報銷模式激勵醫療相關感染的顯著減少，推動了對有效滅菌平台、先進空氣管理系統和強大手部衛生計畫的需求。在該地區營運的製造商通常強調服務網路、培訓和檢驗的性能數據，以支援在急診和門診環境中的應用。同時，歐洲、中東和非洲是一個多元化的地區，監管環境因司法管轄區而異，某些市場的基礎設施差距為可攜式紫外線設備、水處理套件和可擴展的消毒化學品創造了機會，這些設備無需大量資本投入即可部署。與當地經銷商的夥伴關係以及適應不同的臨床工作流程是這些市場成功的關鍵因素。

亞太地區城市中心的技術應用正在快速發展，而周邊醫療環境的醫療能力卻參差不齊。該地區規模較大的手術中心和三級醫院正在採用整合式器械滅菌技術、抗生素塗層器械和集中式空氣處理升級，而規模較小的醫療機構則通常優先考慮經濟高效的手部衛生解決方案、可攜式紫外線設備和模組化水處理設備。在所有地區，供應鏈的彈性、是否符合當地法規以及是否擁有訓練有素的服務技術人員仍然是影響採購決策的關鍵考慮因素。了解區域差異有助於相關人員製化產品、支援模式和培訓計劃，以滿足全球醫療保健系統的不同需求。

製造商、配方師和服務供應商之間的競爭與合作在確定產品性能、採購吸引力和長期臨床結果方面的作用

要成功駕馭感染預防市場，需要了解不同類型公司（從設備製造商到配方商再到服務供應商）的角色和能力。設計空氣淨化系統、紫外線設備和滅菌平台的技術供應商在工程性能、檢驗數據和服務生態系統方面競爭，而消毒劑和手部衛生產品的配方商則必須在功效、材料相容性和皮膚耐受性之間取得平衡。專注於抗菌塗層和設備整合抗菌技術的公司處於材料科學和監管監督的交叉領域，需要強大的生物相容性和抗藥性管理策略。

不僅是產品開發商，而且提供安裝、維護和驗證服務的人員也在持續的臨床表現中發揮關鍵作用。提供預防性保養、快速維修和性能檢驗的服務型公司可以減少停機時間並保持感染控制的有效性。同樣，經銷商和物流合作夥伴對於維持過濾器、滅菌濃縮液和消毒劑填充用等耗材的穩定供應至關重要。設備製造商、製劑製造商和服務網路之間的策略聯盟和夥伴關係日益普遍，從而實現了捆綁銷售，簡化了採購並協調了績效激勵。投資者和企業策略家也關注那些表現出強大上市後監測能力和支持獎勵研究以證明真實世界療效的公司。

為醫療保健和行業領導者提供切實可行的優先行動，以加強感染預防績效、供應鏈彈性和可衡量的臨床結果

行業領導者可以採取具體措施，將洞察轉化為更安全的醫療保健和營運韌性。首先，協調檢驗標準，考慮經過驗證的績效指標和總擁有成本，以確保所選技術能持續提供臨床效益，且不會造成過度的營運負擔。其次，投資服務合約和本地技術能力，以最大限度地減少滅菌設備、空氣處理系統和紫外線設備的停機時間，並確保及時補充耗材。第三，採用綜合感染預防策略，將工程控制、表面和器械消毒以及以行為為中心的干涉措施（例如手部衛生培訓和合規性監測）相結合，以實現縱深防禦。

此外，為了減輕貿易政策變化和零件短缺的影響，我們優先考慮供應商多元化和供應鏈透明度，並參與情境規劃以檢驗緊急方案。我們促進臨床工程合作，在具代表性的臨床環境中試行新技術，並收集可操作的績效數據，為更廣泛的部署提供參考。最後，我們建立採購契約，納入可衡量的績效保證、培訓和實施後評估，使供應商獎勵與臨床結果一致。這些建議旨在適用於各種規模和資源環境的組織，使領導者能夠做出明智的權衡，並部署能夠帶來持續、可衡量價值的感染預防投資。

結合現場訪談、臨床觀察、文獻綜合和供應鏈分析的透明、多方法研究途徑檢驗了可操作的發現

本執行摘要所依據的研究整合了定性和定量方法，以確保研究的穩健性和有效性。主要研究包括對感染預防負責人、設施經理、採購專業人員以及急診和門診護理機構的臨床專家進行結構化訪談，以及實地考察，以觀察技術整合、工作流程影響和維護實踐。次要研究則查閱了關於設備滅菌方法、消毒劑化學成分、空氣品管和臨床指南的同行評審文獻，以基於既定證據提供產品級評估。

影響分析方法將比較技術評估框架（用於評估有效性、相容性和營運影響）與供應鏈風險分析相結合，以繪製採購漏洞圖並制定緩解策略。細分分析利用產品和應用分類法來評估醫療環境中的適用部署方案。與臨床和工程專家進行了交叉檢驗研討會，以完善解讀，並確保建議在現實約束條件下切實可行。最後，對不同資料來源的研究結果進行三角測量，以減少偏差，並突出能夠更好地為決策提供資訊的趨同主題。

整合和策略要務強調綜合防禦、跨部門合作和持續的商業投資，以降低感染風險

最後，感染預防領域正處於曲折點，技術成熟度、臨床實踐的演變以及供應鏈的現實狀況既帶來了挑戰，也帶來了機會。整合淨化空氣、有效的表面和器械消毒、抗生素塗層器械策略以及行為指導式手部衛生方案的多層防禦體系，能夠為預防醫療相關感染提供最強大的防禦。要實施這樣的防禦體系，需要將產品功能與急診科、綜合醫院病房、加護病房、手術室和門診病人設施的具體需求進行仔細匹配，並密切關注供應鏈在政策和貿易變化下的韌性。

相關人員若能採取實證主導的跨職能方法，將臨床負責人、設備工程師、採購負責人和值得信賴的服務合作夥伴聚集在一起，最有能力在病人安全方面取得顯著的改善。持續投資於培訓、績效檢驗和實施後評估，可以長期維持改善。這項結論強調，需要採取果斷行動、務實投資並建立合作夥伴關係，以持續降低感染風險並提高整體醫療品質。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 日益成長的認知度和已證實的有效性推動了紫外線消毒技術在醫療環境中的廣泛應用
  • 整合人工智慧預測分析，識別高風險患者，制定針對性的感染預防策略
  • 開發抗菌銅和銀塗層表面，以減少頻繁接觸區域的病原體傳播
  • 增加一次性醫療設備的使用，以最大限度地減少交叉污染並簡化滅菌工作流程
  • 實施即時病患監測平台，以便及早發現感染指標並縮短反應時間
  • 加強監管和嚴格醫院病原體報告要求推動感染控制投資
  • 抗菌塗料與智慧感測器結合的需求不斷成長，永續監測衛生合規性
  • 用於遠端感染監測和住院患者出院後監測的新興遠端醫療解決方案

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：醫院感染控制市場（依產品類型）

  • 空氣清淨系統
    • HEPA 過濾器
    • 電離系統
    • 紫外線空氣清淨機
  • 抗生素塗層
    • 黏合導管
    • 銀塗層
  • 手部衛生產品
    • 酒精消毒劑
      • 形式
      • 凝膠
      • 液體
    • 抗菌肥皂
    • 擦拭巾
  • 器械消毒器
    • 環氧乙烷滅菌器
    • 巴氏殺菌機
    • 放射線殺菌
    • 蒸氣滅菌器
    • 過氧化氫蒸氣滅菌器
  • 表面消毒劑
    • 酒精消毒劑
    • 氯基消毒劑
    • 過氧化物
    • 季銨化合物
  • 紫外線消毒系統
    • 固定紫外線系統
    • 可攜式紫外線設備
  • 水處理系統
    • 化學處理
    • 過濾系統
    • 紫外線水處理

第9章醫院感染控制市場（按應用）

  • 急診部
    • 成人緊急狀況
    • 兒科急救
  • 普通病房
    • 內科病房
    • 整形外科病房
    • 外科病房
  • 加護病房
    • 成人加護病房
    • 新生兒加護病房
    • 加護病房
  • 手術室
    • 手術期間
    • 術後
    • 術前
  • 門診設施
    • 門診手術中心
    • 診所

第 10 章：按地區分類的醫院感染控制市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第11章醫院感染控制市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 12 章：按國家分類的醫院感染控制市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第13章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Ecolab Inc.
    • 3M Company
    • Danaher Corporation
    • STERIS plc
    • Getinge AB
    • Johnson & Johnson
    • Cardinal Health, Inc.
    • B. Braun Melsungen AG
    • Molnlycke Health Care AB
    • Ansell Limited
Product Code: MRR-035590447FE4

The Hospital Acquired Infection Control Market is projected to grow by USD 61.20 billion at a CAGR of 6.71% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 36.39 billion
Estimated Year [2025] USD 38.79 billion
Forecast Year [2032] USD 61.20 billion
CAGR (%) 6.71%

An authoritative overview establishing the context for modern infection prevention strategies across technologies, clinical settings, and supply chain resilience

Healthcare-acquired infections remain a persistent threat to patient safety, clinical outcomes, and institutional reputation. The convergence of evolving pathogen profiles, tighter regulatory scrutiny, and heightened expectations for facility-level resilience has placed infection prevention at the center of clinical and operational strategy. This introduction frames the multi-dimensional landscape of infection control technologies and clinical applications, setting the stage for deeper analysis across product classes, care settings, and regional dynamics.

The industry today is characterized by rapid technological iteration, cross-disciplinary collaboration, and increased scrutiny of supply chains. Innovations spanning air purification technologies, antibiotic coatings, hand hygiene formulations, instrument sterilization platforms, surface disinfectants, ultraviolet systems, and water treatment processes are being integrated into broader infection prevention programs. Concurrently, healthcare delivery models are shifting care across emergency departments, general wards, intensive care units, operating rooms, and outpatient facilities, each with distinct infection control requirements and operational constraints. These intersecting trends demand integrated strategies that combine engineering controls, surface and instrument decontamination, and behaviorally informed compliance programs.

As stakeholders seek pragmatic pathways to reduce infection incidence, the introduction grounds the reader in the essential considerations that shape procurement, clinical policy, and capital planning. It also establishes the analytical lens used across subsequent sections: a focus on technological efficacy, clinical fit, regulatory alignment, and supply chain resilience to inform evidence-based adoption and scale-up of infection control solutions.

How converging technological innovations, clinical workflow redesigns, and regulatory expectations are reshaping infection prevention across healthcare environments

The infection prevention landscape is undergoing a series of transformative shifts driven by technological advances, regulatory pressures, and changing clinical workflows. Innovations in air management have moved beyond single-purpose filtration to integrated systems that combine HEPA filtration, ionization technologies, and targeted UV air treatment to reduce aerosolized pathogen loads in high-risk areas. Surface and instrument decontamination approaches now pair proven chemistries such as alcohol and chlorine-based disinfectants with peroxygen compounds, quaternary ammonium formulations, and advanced sterilization modalities including vaporized hydrogen peroxide and low-temperature systems, creating layered defenses that complement one another.

Antibiotic coatings for indwelling devices, spanning bonded catheters to silver-based surfaces, are being reevaluated alongside antimicrobial stewardship to balance device-associated infection reduction with resistance considerations. Hand hygiene solutions have diversified to include alcohol-based gels, foams, and liquids alongside antimicrobial soaps and single-use wipes, with delivery formats tailored to workflow and compliance. Ultraviolet disinfection systems have matured into fixed installations and portable devices that support targeted terminal cleaning and rapid room turnover, while water treatment solutions now integrate chemical dosing, filtration, and ultraviolet treatment to address plumbing-related risks.

These technological shifts coincide with operational realignments: intensive care and operating room protocols are increasingly evidence-driven and instrumented, whereas emergency departments and outpatient facilities require rapid, scalable interventions that do not impede throughput. Collectively, these developments are reshaping procurement priorities, capital allocation, and clinical practice guidelines, and they are prompting new collaborations between clinical teams, facilities management, and technology providers.

Assessing the downstream operational and procurement consequences of 2025 tariff shifts on infection control equipment sourcing, supply chain resilience, and clinical continuity

The introduction of tariffs and trade policy adjustments in 2025 has had a cascading effect on supply chains, procurement strategies, and capital planning for infection prevention technologies. Tariff-related cost pressures have influenced the sourcing of critical inputs such as filtration media for HEPA systems, specialized polymers used in coated devices, and components for ultraviolet disinfection equipment, prompting procurement teams to reassess supplier portfolios and consider nearshoring or diversification strategies to maintain continuity of supply.

In response, many health systems and manufacturers have undertaken comprehensive supply chain risk assessments and have adjusted contractual terms to include contingency clauses, alternative sourcing pathways, and strategic inventory buffers for mission-critical items. The shifting cost dynamics have also influenced the relative competitiveness of imported finished goods versus domestically produced alternatives, catalyzing investment in local manufacturing capacity for sterilization equipment, disinfectant formulation, and consumables. Regulatory requirements for validated sterilization processes and product performance have further complicated rapid supplier substitution, motivating cross-functional teams to balance compliance needs with cost containment.

Clinically, these trade dynamics have driven more rigorous evaluation of total cost of ownership, including durability, maintenance requirements, and consumable consumption patterns, rather than relying solely on unit price. Procurement and clinical leaders have increasingly prioritized supplier partnerships that offer service, training, and validated performance data to mitigate operational risk. As a result, tariff-driven pressures have accelerated strategic realignment toward resilient, diversified supply chains and closer collaboration between clinical, procurement, and manufacturing stakeholders.

Segmented insights linking specific infection control product classes to diverse clinical environments and operational constraints to inform procurement and deployment strategies

A nuanced understanding of demand drivers requires segmentation by product type and by clinical application, because the intersection of these dimensions determines clinical utility, procurement priorities, and implementation pathways. Product-wise, air purification technologies encompass HEPA filter-based systems, ionization platforms, and UV-enhanced air purifiers, each offering distinct performance characteristics relevant to airborne pathogen mitigation. Antibiotic coatings, whether applied as bonded catheter surfaces or silver-based finishes, are engineered to reduce device-associated infection risk but must be evaluated for compatibility with device materials and antimicrobial stewardship concerns. Hand hygiene solutions range from alcohol-based sanitizers delivered as gel, foam, or liquid to antimicrobial soaps and single-use hand wipes, with selection influenced by workflow, skin tolerance, and compliance metrics. Instrument sterilization options span steam, ethylene oxide, radiation, low-temperature, and vaporized hydrogen peroxide systems, creating trade-offs between cycle time, material compatibility, and throughput. Surface disinfectants include alcohol and chlorine chemistries, peroxygen compounds, and quaternary ammonium formulations, each suited to specific surface types and contact-time requirements. Ultraviolet disinfection solutions are available as fixed installations and portable devices that serve different operational models, while water treatment strategies combine chemical dosing, filtration, and ultraviolet treatment to address plumbing-related infection vectors.

Application-wise, distinct clinical settings present differentiated requirements and constraints. Emergency departments require solutions that maintain rapid patient flow while providing robust pathogen control across adult and pediatric care areas. General wards, including medical, orthopedic, and surgical units, need scalable interventions that integrate with routine housekeeping and nursing workflows. Intensive care units, covering adult, neonatal, and pediatric subspecialties, demand the highest levels of instrument and environmental control due to patient vulnerability and invasive device prevalence. Operating rooms require coordinated intraoperative, preoperative, and postoperative approaches that prioritize sterility and turnover efficiency. Outpatient facilities, such as ambulatory surgical centers and clinics, seek infection prevention technologies that balance cost-effectiveness with regulatory compliance and high patient throughput. By aligning product selection with the nuances of each care setting, healthcare organizations can achieve performance outcomes that reflect both clinical needs and operational realities.

Regional dynamics and adoption patterns that influence technology selection, regulatory alignment, and support models across major global healthcare markets

Regional dynamics shape the regulatory environment, technology adoption curves, and supply chain pathways for infection prevention solutions. In the Americas, regulatory frameworks and reimbursement models incentivize measurable reductions in healthcare-acquired infections, driving demand for validated sterilization platforms, advanced air management systems, and robust hand hygiene programs. Manufacturers active in this region often emphasize service networks, training, and validated performance data to support adoption across acute and ambulatory settings. Meanwhile, Europe, Middle East & Africa present a heterogeneous landscape where regulatory standards vary across jurisdictions, and infrastructure gaps in some markets create opportunities for portable ultraviolet devices, water treatment packages, and scalable disinfection chemistries that can be deployed without extensive capital works. In these markets, partnerships with local distributors and adaptation to diverse clinical workflows are critical success factors.

Asia-Pacific demonstrates rapid technology uptake in urban centers alongside varied capacity in peripheral healthcare settings. High-volume surgical centers and tertiary hospitals in the region have embraced integrated instrument sterilization technologies, antibiotic-coated devices, and centralized air-handling upgrades, while smaller facilities often prioritize cost-effective hand hygiene solutions, portable UV devices, and modular water treatment units. Across all regions, supply chain resilience, local regulatory alignment, and the availability of trained service technicians remain pivotal considerations that influence procurement decisions. Understanding regional variations enables stakeholders to tailor offerings, support models, and training programs that meet the distinct needs of healthcare systems around the world.

Competitive and collaborative roles of manufacturers, formulators, and service providers that determine product performance, procurement appeal, and long-term clinical outcomes

Successful navigation of the infection prevention market requires an appreciation of the roles and capabilities of different types of companies, from equipment manufacturers to formulators and service providers. Technology vendors that design air purification systems, ultraviolet devices, and sterilization platforms compete on engineering performance, validation data, and service ecosystems, while formulators of disinfectants and hand hygiene products must balance efficacy, material compatibility, and skin tolerability. Companies specializing in antibiotic coatings and device-integrated antimicrobial technologies operate at the intersection of materials science and regulatory scrutiny, requiring robust biocompatibility and resistance management strategies.

Beyond product developers, companies providing installation, maintenance, and validation services play an outsized role in sustained clinical performance. Service-oriented firms that offer preventive maintenance, rapid repair, and performance verification reduce downtime and preserve infection control efficacy. Similarly, distributors and logistics partners are critical to maintaining steady supplies of consumables such as filters, sterilization wrap, disinfectant concentrates, and sanitizer refills. Strategic collaborations and partnerships between device makers, formulators, and service networks are increasingly common, enabling bundled offerings that simplify procurement and align incentives around performance. Investors and corporate strategists are also focusing on companies that demonstrate strong post-market surveillance capabilities and the ability to support clinical studies that substantiate real-world effectiveness.

Practical and prioritized actions for healthcare and industry leaders to enhance infection prevention performance, supply chain resilience, and measurable clinical outcomes

Industry leaders can take concrete steps to translate insights into safer care and operational resilience. First, align procurement criteria with validated performance metrics and total cost of ownership considerations to ensure that chosen technologies deliver sustained clinical benefits without imposing undue operational burden. Second, invest in service agreements and local technical capacity to minimize downtime for sterilization equipment, air handling systems, and ultraviolet devices, and to ensure consumables are replenished promptly. Third, adopt an integrated infection prevention strategy that blends engineering controls, surface and instrument decontamination, and behavior-focused interventions such as hand hygiene training and compliance monitoring to achieve multilayered protection.

Additionally, prioritize supplier diversification and supply chain transparency to mitigate the effects of trade policy shifts and component shortages, and engage in scenario planning to validate contingency options. Foster clinical-engineering collaboration to pilot new technologies in representative care settings, collecting pragmatic performance data that inform broader rollouts. Finally, structure procurement contracts to include measurable performance guarantees, training, and post-implementation evaluation to align vendor incentives with clinical outcomes. These recommendations are designed to be actionable across a range of organizational sizes and resource environments, enabling leaders to make informed trade-offs and to deploy infection prevention investments that deliver consistent, measurable value.

A transparent, multi-method research approach combining field interviews, clinical observation, literature synthesis, and supply chain analysis to validate actionable findings

The research underpinning this executive summary integrates qualitative and quantitative approaches to ensure robustness and relevance. Primary research included structured interviews with infection prevention leaders, facilities managers, procurement professionals, and clinical specialists across acute and ambulatory care settings, supplemented by site visits to observe technology integration, workflow impacts, and maintenance practices. Secondary research reviewed peer-reviewed literature on device sterilization methods, disinfection chemistries, air quality control, and clinical guidelines to ground product-level assessments in established evidence.

Analytical methods combined comparative technology evaluation frameworks, which assess efficacy, compatibility, and operational impact, with supply chain risk analysis to map sourcing vulnerabilities and mitigation strategies. Segmentation analysis drew from product and application taxonomies to evaluate fit-for-purpose deployment scenarios across care settings. Peer validation workshops were conducted with clinical and engineering subject matter experts to refine interpretations and ensure that recommendations are practicable within real-world constraints. Finally, findings were triangulated across data sources to reduce bias and to highlight convergent themes that reliably inform decision-making.

Synthesis and strategic imperatives emphasizing integrated defenses, cross-functional collaboration, and sustained operational investment to reduce infection risk

In closing, the infection prevention landscape is at an inflection point where technological maturity, clinical practice evolution, and supply chain realities converge to create both challenges and opportunities. Layered defenses that integrate air purification, validated surface and instrument decontamination, antibiotic-coated device strategies, and behaviorally informed hand hygiene programs offer the most robust protection against healthcare-acquired infections. Operationalizing these defenses requires careful alignment of product capabilities with the specific demands of emergency departments, general wards, intensive care units, operating rooms, and outpatient facilities, and it necessitates vigilant attention to supply chain resilience in the face of policy and trade shifts.

Stakeholders who adopt an evidence-driven, cross-functional approach-bringing together clinical leadership, facilities engineering, procurement, and trusted service partners-will be best positioned to deliver measurable improvements in patient safety. Continued investment in training, performance verification, and post-implementation evaluation will sustain gains over time. The conclusion underscores the imperative for decisive action, pragmatic investment, and collaborative partnerships to realize durable reductions in infection risk and to enhance overall healthcare quality.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of UV disinfection technology adoption in healthcare settings due to increased awareness and proven efficacy
  • 5.2. Integration of AI-driven predictive analytics to identify high-risk patients for targeted infection prevention strategies
  • 5.3. Development of antimicrobial copper and silver-coated surfaces to reduce pathogen transmission on high-touch areas
  • 5.4. Rise of single-use disposable medical devices to minimize cross-contamination and streamline sterilization workflows
  • 5.5. Implementation of real-time patient monitoring platforms for early detection of infection indicators and improved response times
  • 5.6. Increased regulatory scrutiny and stricter reporting requirements for hospital pathogens driving infection control investments
  • 5.7. Growing demand for combined antimicrobial coatings and smart sensors to continuously monitor hygiene compliance
  • 5.8. Emergence of telemedicine solutions for remote infection surveillance and post-discharge monitoring of hospital patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hospital Acquired Infection Control Market, by Product Type

  • 8.1. Air Purification Systems
    • 8.1.1. HEPA Filters
    • 8.1.2. Ionization Systems
    • 8.1.3. UV Air Purifiers
  • 8.2. Antibiotic Coatings
    • 8.2.1. Bonded Catheters
    • 8.2.2. Silver Coatings
  • 8.3. Hand Hygiene Products
    • 8.3.1. Alcohol Based Sanitizers
      • 8.3.1.1. Foam
      • 8.3.1.2. Gel
      • 8.3.1.3. Liquid
    • 8.3.2. Antimicrobial Soaps
    • 8.3.3. Hand Wipes
  • 8.4. Instrument Sterilization Equipment
    • 8.4.1. Ethylene Oxide Sterilizers
    • 8.4.2. Low Temperature Sterilizers
    • 8.4.3. Radiation Sterilizers
    • 8.4.4. Steam Sterilizers
    • 8.4.5. Vaporized Hydrogen Peroxide Sterilizers
  • 8.5. Surface Disinfectants
    • 8.5.1. Alcohol Based Disinfectants
    • 8.5.2. Chlorine Based Disinfectants
    • 8.5.3. Peroxygen Compounds
    • 8.5.4. Quaternary Ammonium Compounds
  • 8.6. Ultraviolet Disinfection Systems
    • 8.6.1. Fixed UV Systems
    • 8.6.2. Portable UV Devices
  • 8.7. Water Treatment Systems
    • 8.7.1. Chemical Treatment
    • 8.7.2. Filtration Systems
    • 8.7.3. UV Water Treatment

9. Hospital Acquired Infection Control Market, by Application

  • 9.1. Emergency Departments
    • 9.1.1. Adult Emergency
    • 9.1.2. Pediatric Emergency
  • 9.2. General Wards
    • 9.2.1. Medical Wards
    • 9.2.2. Orthopedic Wards
    • 9.2.3. Surgical Wards
  • 9.3. Intensive Care Units
    • 9.3.1. Adult ICU
    • 9.3.2. Neonatal ICU
    • 9.3.3. Pediatric ICU
  • 9.4. Operating Rooms
    • 9.4.1. Intraoperative
    • 9.4.2. Postoperative
    • 9.4.3. Preoperative
  • 9.5. Outpatient Facilities
    • 9.5.1. Ambulatory Surgical Centers
    • 9.5.2. Clinics

10. Hospital Acquired Infection Control Market, by Region

  • 10.1. Americas
    • 10.1.1. North America
    • 10.1.2. Latin America
  • 10.2. Europe, Middle East & Africa
    • 10.2.1. Europe
    • 10.2.2. Middle East
    • 10.2.3. Africa
  • 10.3. Asia-Pacific

11. Hospital Acquired Infection Control Market, by Group

  • 11.1. ASEAN
  • 11.2. GCC
  • 11.3. European Union
  • 11.4. BRICS
  • 11.5. G7
  • 11.6. NATO

12. Hospital Acquired Infection Control Market, by Country

  • 12.1. United States
  • 12.2. Canada
  • 12.3. Mexico
  • 12.4. Brazil
  • 12.5. United Kingdom
  • 12.6. Germany
  • 12.7. France
  • 12.8. Russia
  • 12.9. Italy
  • 12.10. Spain
  • 12.11. China
  • 12.12. India
  • 12.13. Japan
  • 12.14. Australia
  • 12.15. South Korea

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Analysis
    • 13.3.1. Ecolab Inc.
    • 13.3.2. 3M Company
    • 13.3.3. Danaher Corporation
    • 13.3.4. STERIS plc
    • 13.3.5. Getinge AB
    • 13.3.6. Johnson & Johnson
    • 13.3.7. Cardinal Health, Inc.
    • 13.3.8. B. Braun Melsungen AG
    • 13.3.9. Molnlycke Health Care AB
    • 13.3.10. Ansell Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. AMERICAS HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. NORTH AMERICA HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. LATIN AMERICA HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. EUROPE, MIDDLE EAST & AFRICA HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. EUROPE HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. MIDDLE EAST HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AFRICA HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASEAN HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GCC HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPEAN UNION HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. BRICS HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. G7 HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. NATO HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. HOSPITAL ACQUIRED INFECTION CONTROL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. HOSPITAL ACQUIRED INFECTION CONTROL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HOSPITAL ACQUIRED INFECTION CONTROL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY AIR PURIFICATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HEPA FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HEPA FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HEPA FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HEPA FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HEPA FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HEPA FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY IONIZATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY IONIZATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY IONIZATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY IONIZATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY IONIZATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY IONIZATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV AIR PURIFIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV AIR PURIFIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV AIR PURIFIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV AIR PURIFIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV AIR PURIFIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV AIR PURIFIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC COATINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY BONDED CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY BONDED CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY BONDED CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY BONDED CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY BONDED CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY BONDED CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SILVER COATINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SILVER COATINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SILVER COATINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SILVER COATINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SILVER COATINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SILVER COATINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND HYGIENE PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED SANITIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FOAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FOAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FOAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FOAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FOAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FOAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SOAPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SOAPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SOAPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SOAPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SOAPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SOAPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND WIPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND WIPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND WIPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND WIPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND WIPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY HAND WIPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INSTRUMENT STERILIZATION EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ETHYLENE OXIDE STERILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ETHYLENE OXIDE STERILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ETHYLENE OXIDE STERILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ETHYLENE OXIDE STERILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ETHYLENE OXIDE STERILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ETHYLENE OXIDE STERILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LOW TEMPERATURE STERILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LOW TEMPERATURE STERILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LOW TEMPERATURE STERILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LOW TEMPERATURE STERILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LOW TEMPERATURE STERILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY LOW TEMPERATURE STERILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY RADIATION STERILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY RADIATION STERILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY RADIATION STERILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY RADIATION STERILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY RADIATION STERILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY RADIATION STERILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY STEAM STERILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY STEAM STERILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY STEAM STERILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY STEAM STERILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY STEAM STERILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY STEAM STERILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY VAPORIZED HYDROGEN PEROXIDE STERILIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY VAPORIZED HYDROGEN PEROXIDE STERILIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY VAPORIZED HYDROGEN PEROXIDE STERILIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY VAPORIZED HYDROGEN PEROXIDE STERILIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY VAPORIZED HYDROGEN PEROXIDE STERILIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY VAPORIZED HYDROGEN PEROXIDE STERILIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURFACE DISINFECTANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED DISINFECTANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED DISINFECTANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED DISINFECTANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED DISINFECTANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED DISINFECTANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ALCOHOL BASED DISINFECTANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHLORINE BASED DISINFECTANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHLORINE BASED DISINFECTANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHLORINE BASED DISINFECTANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHLORINE BASED DISINFECTANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHLORINE BASED DISINFECTANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHLORINE BASED DISINFECTANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEROXYGEN COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEROXYGEN COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEROXYGEN COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEROXYGEN COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEROXYGEN COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEROXYGEN COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY QUATERNARY AMMONIUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY QUATERNARY AMMONIUM COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY QUATERNARY AMMONIUM COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY QUATERNARY AMMONIUM COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY QUATERNARY AMMONIUM COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY QUATERNARY AMMONIUM COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ULTRAVIOLET DISINFECTION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FIXED UV SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FIXED UV SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FIXED UV SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FIXED UV SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FIXED UV SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FIXED UV SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PORTABLE UV DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PORTABLE UV DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PORTABLE UV DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PORTABLE UV DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PORTABLE UV DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PORTABLE UV DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY WATER TREATMENT SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHEMICAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHEMICAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHEMICAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHEMICAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHEMICAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY CHEMICAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FILTRATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FILTRATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FILTRATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY FILTRATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV WATER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV WATER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV WATER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV WATER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV WATER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY UV WATER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ADULT EMERGENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ADULT EMERGENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ADULT EMERGENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ADULT EMERGENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ADULT EMERGENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ADULT EMERGENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEDIATRIC EMERGENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEDIATRIC EMERGENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEDIATRIC EMERGENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEDIATRIC EMERGENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEDIATRIC EMERGENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY PEDIATRIC EMERGENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY GENERAL WARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY MEDICAL WARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY MEDICAL WARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY MEDICAL WARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY MEDICAL WARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY MEDICAL WARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY MEDICAL WARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ORTHOPEDIC WARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ORTHOPEDIC WARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ORTHOPEDIC WARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ORTHOPEDIC WARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ORTHOPEDIC WARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY ORTHOPEDIC WARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURGICAL WARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURGICAL WARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURGICAL WARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURGICAL WARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURGICAL WARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY SURGICAL WARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INTENSIVE CARE UNITS, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL HOSPITAL ACQUIRED INFECTION CONTROL MARKET SIZE, BY INTENSIVE CARE UNI